TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Serum Ca(2+) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal Ca(2+) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine Ca(2+) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ca(2+) imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioequivalence of FDC to individual formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rates of target lesion restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Emergency hospital admission rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Emergency department attendance rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Outpatient visit rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Recovery to normal tympanic membrane or regression to grade 1 atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in middle ear pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of pure-tone air-conduction threshold averages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Renal and liver laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Systolic carotid diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RQLQ total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean incremental QALY of intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Major paravalvular leakage requiring reoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from any explant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of children with no progression of treated lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in BPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rates (Hamilton Rating Scale for Depression score, ≤9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein:HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EPS-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Bioequivalence of citalopram to cipramil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of premature LH surges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glove perforation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Roland Morris Disability change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate of incision infection and delayed healing
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in VO2 P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen uptake at the first ventilatory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT-20 (Sino-Nasal Outcome Test-20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of physical doses in the treatment target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of physical doses in OaR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of BED doses in healthy tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 year risk of coronary heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean HbA(1c) at recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood pressure > or =140/90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious bacterial infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total urine masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal Clinically Important Improvement (MCII)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pattern of prescription of asthma medicines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of symptoms and negative Dix-Hallpike test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucolipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful treatment with negative titers of β‐hCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time interval for β‐hCG to become undetectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelium-dependent dilation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients achieving > 50% excess weight loss (EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac deaths incidence
Endpoint domain: Mortality/survival
Primary endpoint: Percent reduction of LDL-C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in skin hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in intercellular lipid length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Risk of AIDS events
Endpoint domain: Mortality/survival
Primary endpoint: Risk of immune reconstitution inflammatory syndrome (IRIS)
Endpoint domain: Mortality/survival
Primary endpoint: Potential side effects following treatment
Endpoint domain: Adverse events/effects
Primary endpoint: death or major cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Mean improvement in morning PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skin viscosity decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of small-bore feeding tube occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving a steady‐state SDC of 0.5‐0.9 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D questionnaire utility values
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: longitudinal progression of damage of the large joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relief of osteoarticular pain and stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BSSI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic inflammatory response (IL-6 levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duodenal, jejunal and ileal distention scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wall visualization scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: INR prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Histamine-induced skin reaction inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum melatonin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target revascularization incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of optotypes presented
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitting diastolic blood pressure of 90 mm Hg or below
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depression rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tattoo clearance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Textural changes score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse reactions frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Productivity status at follow-up
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: maximum intraurethral pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in total and resilience scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major complications after CABG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: risk of stroke recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Shooting performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without bloody stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to bloody stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of artemether-lumefantrine regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: catheter-related infections
Endpoint domain: Adverse events/effects
Primary endpoint: Bacterial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvements in biomarkers of effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygenation index value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: APACHEII scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine series completion rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Issues on treatment compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Autistic life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stanford Sleepiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Relative Attachment Level (RAL) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance-vessel endothelium-dependent vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure rate of electrodes
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of superficial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Need for reimplantation of electrodes
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time spent in euglycemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to treatment (50% reduction in VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete recovery or much improvement at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate depression treatment by discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean total area under the plasma concentration-time curve of glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean elimination half-life of glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median monthly rate of decline in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of households purchasing anti-mosquito products
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean expenditure on anti-mosquito products
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Levels of cortisol, testosterone, and progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total cholesterol/HDL ratio (atherogenic index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Smoking cessation rates at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total energy intake from a standardized breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of developing T2DM
Endpoint domain: Mortality/survival
Primary endpoint: all-cause 30-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: time to primary endpoint (hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: life span of dead children
Endpoint domain: Mortality/survival
Primary endpoint: 5-year sustained smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to T-CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of the need for T-CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in bladder volumes at first sensation of filling (FSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in maximum fill volume (MFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success rate (>or=50% improvement in primary voiding diary variables)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: difficulty of performing activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: nutritional risk index (NRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: irPFS
Endpoint domain: Mortality/survival
Primary endpoint: Pain at biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced urinary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thoughts of death
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficult delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity (hematologic and nonhematologic)
Endpoint domain: Adverse events/effects
Primary endpoint: Difficulty score during colonoscope insertion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient recovery
Endpoint domain: Mortality/survival
Primary endpoint: Activity ability of daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: greater emotional role functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fewer negative views of relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Restoration of physiological stomach contractions frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient's pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Personal recovery improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to any mood relapse
Endpoint domain: Mortality/survival
Primary endpoint: Percentage retained on naltrexone treatment at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Molecular Response (MMR)
Endpoint domain: Mortality/survival
Primary endpoint: Symptomatology improvement in BMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in temperature (Ta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year FFAF rate
Endpoint domain: Mortality/survival
Primary endpoint: grade of effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average percent change in the effusion grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate relief of IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical curvature improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height of the fused segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final TIMI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: final TIMI frame count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: final myocardial blush grade value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self-report of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Energy intake assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recovery of viable bronchial epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful establishment of primary bronchial epithelial cell cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects attributable to sampling
Endpoint domain: Adverse events/effects
Primary endpoint: mean maximum urethral pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean urethral closure pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Liking VAS E(max)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Drug Liking E(8h)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Take Drug Again E(8h)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eye injury rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of ecstasy use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cannabis use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to use meth/amphetamine and ecstasy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in tinnitus variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of herbal medicine services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chemical pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Success rate for target vein dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verbal or somatic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hiccups on esophageal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of fissure-attached malignant nodules
Endpoint domain: Mortality/survival
Primary endpoint: repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIN3+ prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean vertigo scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of vertigo-associated vegetative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Hangover Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived latency to sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Low frequency (LF) power during orthostatic stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxidative stress indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessability of BVS by MSCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-device minimal lumen diameter by MSCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes